Dr Rachel Conyers
Dr Rachel Conyers
Details
Role
Team Leader / Clinical Research Fellow
Group
Cancer Therapies
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s Hospital, Melbourne; and the Team Leader of Pharmacogenomics and recipient of Clinician Scientist Fellowship (since 2016) at Murdoch Children’s Research Institute. She is a recognised national leader in pharmacogenomics and rare toxicities as demonstrated by her position as the lead for Pharmacogenomics implementation and discovery through the Victorian Paediatric Cancer Consortium (VPCC) and co-chair of pharmacogenomics working group in the Zero Childhood Cancer Program.
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s...
A/Prof Rachel Conyers is a clinician scientist who trained in Paediatric Oncology with specialisation in leukaemia, lymphoma and bone marrow transplantation. She is the current clinical lead of Bone Marrow Transplantation at The Royal Children’s Hospital, Melbourne; and the Team Leader of Pharmacogenomics and recipient of Clinician Scientist Fellowship (since 2016) at Murdoch Children’s Research Institute. She is a recognised national leader in pharmacogenomics and rare toxicities as demonstrated by her position as the lead for Pharmacogenomics implementation and discovery through the Victorian Paediatric Cancer Consortium (VPCC) and co-chair of pharmacogenomics working group in the Zero Childhood Cancer Program.
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
A/Prof Conyers has independently attained funding towards the establishment of the Australian Cardio Oncology Registry and Biobank and its associated research studies and more recently, the Pharmacogenomics program. This is demonstrated by $3.2M of MRFF, NHMRC, government and philanthropic funding (CIA), with an additional $10.7M funding as CIC, CID, CIG. She has published 67 articles to date (1240 citations, 16 h-index,) with a > 1 field weighted citation impact (SCOPUS) for Clinical Pharmacology and Pharmacogenetics (3.2) and Cardiotoxicity (1.2).
A/Prof Conyers’s international leadership in pharmacogenetics and rare toxicities is demonstrated by her position as principal investigator of cardiac toxicity working groups for Ponte De Legno Acute Lymphoblastic Leukaemia Working Group (Europe) and contribution to the Cardiovascular Task Force for Children’s Oncology Group (US). As Team Leader of Pharmacogenetics at Murdoch Children’s Research Institute, she leads a talented multi-disciplinary team with a program of work in discovery and implementation of pharmacogenomics.
A/Prof Conyers has further developed her leadership skills by studies at Melbourne Business School Leadership in Health Care (Scholarship Recipient Victorian Comprehensive Cancer Centre), participation in a Masters of Business Administration (MBA) at Melbourne Business School with a Deans Commendation (Business Strategy, 2021), and completion of the Royal Australasian College of Medical Administration Leadership for Clinicians Program (2021, AFRACMA).
Top Publications
- Lange, PW, Turbić, A, Soh, CH, Clayton-Chubb, D, Lim, WK, Conyers, R, Watson, R, Maier, AB. Melatonin does not reduce delirium severity in hospitalized older adults: Results of a randomized placebo-controlled trial.. J Am Geriatr Soc 2024 view publication
- Singleton, AC, Redfern, J, Diaz, A, Koczwara, B, Nicholls, SJ, Negishi, K, La Gerche, A, Playford, D, Conyers, R, Cehic, DA, et al. Integrating CardioOncology Across the Research Pipeline, Policy, and Practice in Australia-An Australian Cardiovascular Alliance Perspective.. Heart Lung Circ 2024 view publication
- McLeman, LM, Glaser, A, Conyers, R, Deans, AJ. A systematic review investigating advances in gene therapy for Fanconi anemia over the last three decades. Frontiers in Hematology 2: 2024 view publication
- Grimshaw, SL, Taylor, NF, Conyers, R, Shields, N. Promoting positive physical activity behaviours in children undergoing acute cancer treatment: feasibility of the CanMOVE intervention.. Braz J Phys Ther 28(1) : 100577 2024 view publication
- Toro, C, Felmingham, B, Jhadav, M, Celermajer, DS, La Gerche, A, O'Sullivan, J, Kumar, S, Mateos, MK, Fulbright, J, Govender, D, et al. Lessons learnt in the first year of an Australian pediatric cardio oncology clinic.. Cardiooncology 9(1) : 45 2023 view publication
Page 1 of 15
Career information
Share //
